Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.54 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.51 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.49 |
| ▸ | CACNB4 | O00305 | 2/20 | 0.47 |
| ▸ | CACNA1A | O00555 | 2/20 | 0.47 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.47 |
| ▸ | CACNG3 | O60359 | 2/20 | 0.47 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.47 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.47 |
| ▸ | CACNB3 | P54284 | 2/20 | 0.47 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.47 |
| ▸ | CACNG7 | P62955 | 2/20 | 0.47 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.47 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.47 |
| ▸ | CACNB1 | Q02641 | 2/20 | 0.47 |
| ▸ | CACNG1 | Q06432 | 2/20 | 0.47 |
| ▸ | CACNB2 | Q08289 | 2/20 | 0.47 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.47 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21606956 | 0.93 | GPR119 (0.50) | GPR119CHEK2NPBWR1MCHR1CACNB4 | |
| SCHEMBL21606910 | 0.90 | GPR119 (0.50) | GPR119CHEK2NPBWR1MCHR1STS | |
| SCHEMBL24091438 | 0.89 | GPR119 (0.60) | GPR119CHEK2NPBWR1MCHR1PDE4A | |
| SCHEMBL21606981 | 0.88 | GPR119 (0.46) | GPR119CHEK2NPBWR1MCHR1CACNB4 | |
| SCHEMBL7722029 | 0.87 | STS (0.57) | GPR119CHEK2NPBWR1MCHR1CACNB4 | |
| SCHEMBL25763141 | 0.86 | CHEK2 (0.49) | GPR119CHEK2NPBWR1MCHR1CACNB4 | |
| SCHEMBL21606918 | 0.86 | GPR119 (0.55) | GPR119CHEK2NPBWR1MCHR1PDE4A | |
| SCHEMBL190497 | 0.85 | GPR119 (0.53) | GPR119CHEK2NPBWR1MCHR1CACNB4 | |
| SCHEMBL29495616 | 0.85 | GPR119 (0.53) | GPR119CHEK2NPBWR1MCHR1CACNB4 | |
| SCHEMBL24091563 | 0.85 | GPR119 (0.56) | GPR119CHEK2NPBWR1MCHR1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4643954-A2 | NOVEL HETEROCYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Daewoong Pharmaceutical Co., Ltd. (KR) | 2025-11-05 | — | — | EP | disclosed |
| CN-112638910-B | New heterocyclic amine derivatives and pharmaceutical compositions containing the same | 株式会社大熊制药 | 2024-06-11 | — | — | CN | disclosed |
| US-20220064155-A1 | NOVEL HETEROCYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2022-03-03 | — | — | US | disclosed |
| EP-3845530-A1 | NOVEL HETEROCYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Daewoong Pharmaceutical Co., Ltd. (KR) | 2021-07-07 | — | — | EP | disclosed |
| EP-3845530-A1 | NOVEL HETEROCYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Daewoong Pharmaceutical Co., Ltd. (KR) | 2021-07-07 | — | — | EP | disclosed |
| US-20210122763-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN-CILAG S.A. (ES) | 2021-04-29 | — | — | US | disclosed |
| CN-112638910-A | Novel heterocyclic amine derivatives and pharmaceutical compositions comprising the same | 株式会社大熊制药 | 2021-04-09 | — | — | CN | disclosed |
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| WO-2020045941-A1 | NOVEL HETEROCYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 대웅제약 | 2020-03-05 | — | — | WO | disclosed |
| WO-2020045941-A1 | NOVEL HETEROCYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 대웅제약 | 2020-03-05 | — | — | WO | disclosed |
| WO-2019243530-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210122763-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | GPR119 1166/4885CHEK2 575/4885NPBWR1 4748/4885 |
| US-20220064155-A1 | NOVEL HETEROCYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | H1-5, H1-2, SSB | GPR119 309/4885CHEK2 579/4885NPBWR1 2982/4885 |
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | GPR119 236/4885CHEK2 3208/4885NPBWR1 3011/4885 |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | GPR119 236/4885CHEK2 3208/4885NPBWR1 3011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.